Faculty Opinions recommendation of Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.

Author(s):  
Pamela Warner
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Simon E. Kolstoe ◽  
David Carpenter

Abstract Background In their paper “Research approvals iceberg: how a ‘low-key’ study in England needed 89 professionals to approve it and how we can do better” Petrova and Barclay highlight concerns with the health research regulatory environment in the UK. Discussion As long-standing chairs of NHS research ethics committees, researchers, and also academics in research ethics, we are also often frustrated with the regulatory process in the UK. However, we think that Petrova and Barclay’s analysis is misleading because it conflates research ethics with governance and funding processes, thus failing to adequately distinguish between the national coordinating function of the Health Research Authority, local research governance processes, and interactions with research sponsors and/or the Clinical Research Network.


2016 ◽  
Vol 130 (S2) ◽  
pp. S216-S217
Author(s):  
N Stafford

AbstractHead and neck cancer clinical research is thriving. Infrastructure for clinical research is supported through the National Institute for Health Research Clinical Research Network with operates through 15 local clinical research networks for studies within the UK Clinical Research Network Portfolio. The National Clinical Research Institute is a partnership of UK cancer research funders that support high-quality cancer research, although the National Institute for Health Research also has funding streams that will fund cancer-related research. Their websites provide up-to-date information regarding ongoing research projects. Other specialty organisations such as the British Association of Head and Neck Oncologists play important subsidiary roles in supporting research.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6091-6091 ◽  
Author(s):  
Matthew Cooper ◽  
Karen Poole ◽  
David A. Cameron ◽  
Robert Haward ◽  
Peter John Selby ◽  
...  

6091 Background: The National Institute for Health Research Cancer Research Network (NCRN) was established in 2001 in England, United Kingdom to improve cancer patient outcomes by improving the coordination, integration and speed of cancer research. Methods: Baseline recruitment of cancer patients in England to clinical studies was around 4% of incident population. Research Networks were established initially in England (NCRN) and then across the UK, co-terminus with clinical cancer service networks, and a per capita based funding model used to provide a research infrastructure to support recruitment to a nationally defined research portfolio. Results: Within 3 years, as the networks were established, recruitment of patients to studies doubled from 10,000 to 20,000 cancer patients per year. Recruitment has continued to increase year on year, supported initially by underspend that had accrued from earlier years in the life of NCRN, and more recently from additional resources invested via the NIHR comprehensive networks. Data for 2010/11 show that over 45,000 cancer patients are now recruited into portfolio studies in England each year, with over 50,000 across the whole of the UK. Conclusions: Dedicated, targeted, clinician-led National Health Service investment into supporting national portfolio studies, has delivered an unprecedented five-fold increase in recruitment of cancer patients into clinical trials across the United Kingdom. This required coordinated research infrastructure, close cooperation with research funders, particularly Cancer Research UK and the National Cancer Research Institute, and the enthusiasm and hard work of many clinicians, patients and others working to deliver clinical cancer care in the National Health Service in the United Kingdom.


BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e043750
Author(s):  
Stephen Jennings ◽  
Sally Anstey ◽  
Janet Bower ◽  
Alison Brewster ◽  
John Buckman ◽  
...  

IntroductionThere is a global interest in cancer immunotherapy. Clinical trials have found that one group, immune checkpoint inhibitors (ICIs), has demonstrated clinical benefits across various cancers. However, research focused on the experiences of people affected by cancer who have undergone this treatment using qualitative methodology is currently limited. Moreover, little is known about the experiences and education needs of the healthcare staff supporting the people receiving these immunotherapies. This study therefore seeks to explore the experiences of using ICIs by both the people affected by cancer and the healthcare professionals who support those people, and use the findings to make recommendations for ICI supportive care guidance development, cancer immunotherapy education materials for healthcare professionals, cancer policy and further research.Methods and analysisPatient participants (n=up to 30) will be recruited within the UK. The sample will incorporate a range of perspectives, sociodemographic factors, diagnoses and ICI treatments, yet share some common experiences. Healthcare professionals (n=up to 15) involved in supporting people receiving immunotherapy will also be recruited from across the UK. Data will be generated through in-depth, semistructured interviews. Reflexive thematic analysis will be used to obtain thorough understanding of individual’s perspectives on, and experiences of, immunotherapy. Study dates are as follows: December 2019–March 2022.Ethics and disseminationThe research will be performed in accordance with the UK Policy for Health and Social Care Research and Cardiff University’s Research Integrity and Governance Code of Practice (2018). The study received ethical approval from the West Midlands and Black Country Research Ethics Committee in October 2019. Health Research Authority and Health and Care Research Wales approvals were confirmed in December 2019. All participants will provide informed consent. Findings will be published in peer-reviewed journals, non-academic platforms, the Macmillan Cancer Support website, disseminated at relevant national and international conferences and presented via a webinar. The study is listed on the National Institute for Health Research (NIHR) Clinical Research Network Central Portfolio.


Sign in / Sign up

Export Citation Format

Share Document